Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
13-valent Pneumococcal Conjugate Vaccine in Healthy Infants
NCT00384059Phase 3Completed
- Sponsor
- Pfizer
- Start
- Oct 2006
- Primary completion
- Oct 2008
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Prevnar 13 in pneumococcal disease (2 arms), sponsored by Pfizer. Primary endpoints: Percentage of Participants Achieving a Meningococcal C Serum Bactericidal Assay (SBA) Titer ≥1:8 and Predefined Antibody Levels for Pertussis and Haemophilus Influenzae Type b in 13vPnC Group…, Geometric Mean Titer (GMT) of Meningococcal C Antigen as Measured by SBA in 13vPnC Group Relative to 7vPnC Group After the 2-dose Infant Series and 4 more. Started Oct 2006; status: completed.
02
Drugs
Prevnar 13
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT00384059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00384059.